Zyryanov S K, Butranova O I, Gaidai D S, Kryshen K L
People's Friendship University of Russia.
City Clinical Hospital №24.
Ter Arkh. 2021 Jan 10;93(1):114-124. doi: 10.26442/00403660.2021.01.200551.
Routinely the influenza virus significantly contributes to the formation of the annual incidence of acute respiratory infections, with a peak in winter season. The high level of mutagenic potential of influenza viruses is a standard factor determining the complexity of the rational choice of pharmacotherapy. The upcoming epidemiological season 20202021 brings additional challenges for health care practitioners mediated by the widespread prevalence in the human population of a new infection caused by the SARS-CoV-2 virus affecting the respiratory system among many organs and systems. An adequate choice of pharmacotherapy tools should be based on high efficiency and safety of drugs, with a possible reduction in such negative factors as polypharmacy. This review includes comparative pharmacological characteristics of drugs with activity against RNA viruses, along with parameters of their clinical efficacy.
通常情况下，流感病毒在急性呼吸道感染的年发病率形成中起重要作用，在冬季达到高峰。流感病毒的高诱变潜力是决定合理选择药物治疗复杂性的一个标准因素。即将到来的2020-2021年流行季节给医护人员带来了额外的挑战，这是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒在人群中广泛传播引起的一种新感染介导的，该病毒会影响多个器官和系统中的呼吸系统。药物治疗工具的合理选择应基于药物的高效性和安全性，并尽可能减少诸如多药合用等负面因素。本综述包括对具有抗RNA病毒活性的药物的比较药理学特征及其临床疗效参数。
